Literature DB >> 16440713

[Facial edema and pruritus after intravenous injection of midazolam].

Ayako Uchimura1, Hisanori Yogo, Ichidai Kudoh, Akito Ohmura.   

Abstract

Midazolam is a short-acting benzodiazepine commonly used for conscious sedation for a variety of procedures. Severe adverse reactions, including respiratory depression, respiratory arrest, and anaphylactoid reaction, have been described by manufacturers. We report a patient who developed facial edema after iv injection of midazolam during caesarian section. A 26-year-old woman with a history of atopy and pollen allergy was scheduled for caesarian section. Spinal anesthesia was induced with bupivacaine without significant medical problems. Shortly after receiving 2 mg of iv midazolam 15 minutes after delivery for conscious sedation, she developed pruritus and severe facial edema. Airway obstruction did not occur and no specific medical treatment was necessary. However she was not able to open her eyes for 8 hours because of severe eyelid swelling. We should be more careful in administering midazolam which is generally regarded as safe and well tolerated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16440713

Source DB:  PubMed          Journal:  Masui        ISSN: 0021-4892


  4 in total

1.  Anaphylactoid-like Reaction to Midazolam During Oral and Maxillofacial Surgery.

Authors:  Terumi Ayuse; Shinji Kurata; Takao Ayuse
Journal:  Anesth Prog       Date:  2015

Review 2.  [Mastocytosis. A challenge in anaesthesiology].

Authors:  F M Konrad; K E Unertl; T H Schroeder
Journal:  Anaesthesist       Date:  2009-12       Impact factor: 1.041

3.  Innocent unilateral facial swelling after endoscopic sphincterotomy.

Authors:  Panagiotis Katsinelos; Stergios Gkagkalis; Kostas Fasoulas; Grigoris Chatzimavroudis; Christos Zavos; Jannis Kountouras
Journal:  Ann Gastroenterol       Date:  2013

4.  Hypersensitivity reaction to midazolam: a case of cardio-respiratory failure.

Authors:  Eleonora Nucera; Arianna Aruanno; Alessandro Buonomo; Giuseppe Parrinello; Angela Rizzi
Journal:  Postepy Dermatol Alergol       Date:  2021-01-06       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.